PRODUCT MONOGRAPH

ATACAND®
candesartan cilexetil tablets
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AT₁ Receptor Blocker

AstraZeneca Canada Inc.
1004 Middlegate Road
Mississauga, Ontario
L4Y 1M4
www.astrazeneca.ca

Date of Revision: February 19, 2016
Submission Control Number: 187873

ATACAND® is a registered trademark of the AstraZeneca group of companies. Manufactured under license from Takeda Pharmaceutical Company Ltd.
ATACAND®
candesartan cilexetil tablets

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>All Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Tablets: 4 mg, 8 mg, 16 mg and 32 mg</td>
<td>Calcium carboxymethylcellulose, hydroxypropyl cellulose, iron oxide (except 4 mg tablets), lactose, magnesium stearate, maize starch, polyethylene glycol</td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE

ATACAND (candesartan cilexetil) is indicated for:

- **Hypertension**
  - The treatment of mild to moderate essential hypertension.
  - ATACAND may be used alone or concomitantly with thiazide diuretics.
  - The safety and efficacy of concurrent use with calcium channel blockers have not been established.

- **Heart Failure**
  - The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in addition to standard therapy, with or without an ACE inhibitor.
Geriatrics (> 65 years of age): No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Pediatrics (6 to 17 years of age):

- **Hypertension**
  ATACAND is indicated for the treatment of essential hypertension in children and adolescents 6 to 17 years of age (see CLINICAL TRIALS).

- **Heart Failure**
  The safety and efficacy of ATACAND in the treatment of heart failure has not been established in children and adolescents <18 years.

CONTRAINDICATIONS

ATACAND (candesartan cilexetil) is contraindicated in:

- Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see DOSAGE FORMS, COMPOSITION AND PACKAGING section of the product monograph.

- Children aged <1 year.

- Pregnant women (see WARNINGS AND PRECAUTIONS, Special Populations, Pregnant Women).

- Nursing women (see WARNINGS AND PRECAUTIONS, Special Populations, Nursing Women).

- Combination with aliskiren-containing drugs in patients with diabetes mellitus (type 1 or type 2) or moderate to severe renal impairment (GFR < 60 mL/min/1.73m$^2$) (see WARNINGS and PRECAUTIONS, Dual Blockade of the Renin-Angiotensin System (RAS) and Renal, and DRUG INTERACTIONS, Dual Blockade of the Renin-Angiotensin-System (RAS) with ARBs, ACEIs or aliskiren-containing drugs).

- Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.
WARNINGS AND PRECAUTIONS

**Serious Warnings and Precautions**

When used in pregnancy, angiotensin receptor (AT₁) blockers (ARBs) can cause injury or even death of the developing fetus. When pregnancy is detected, ATACAND should be discontinued as soon as possible (see WARNINGS AND PRECAUTIONS, Special Populations, Pregnant Women).

**Cardiovascular**

**Dual blockade of the Renin-Angiotensin System (RAS)**

There is evidence that co-administration of angiotensin receptor antagonists (ARBs), such as ATACAND, or of angiotensin converting enzyme inhibitors (ACEIs) with aliskiren increases the risk of hypotension, syncope, stroke, hyperkalemia and deterioration of renal function, including renal failure, in patients with diabetes mellitus (type 1 or type 2) and/or moderate to severe renal impairment (GFR < 60 mL/min/1.73m²). Therefore, the use of ATACAND in combination with aliskiren-containing drugs is contraindicated in these patients (see CONTRAINDICATIONS).

Further, co-administration of ARBs, including ATACAND, with other agents blocking the RAS, such as ACEIs or aliskiren-containing drugs, is generally not recommended in other patients, since such treatment has been associated with an increased incidence of severe hypotension, decreased renal function (including acute renal failure), and hyperkalemia.

Avoid the concomitant use of ACE inhibitors and ARBs in patients with diabetic nephropathy.

If dual blockade therapy is considered necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.

**Hypotension**

Occasionally, symptomatic hypotension has occurred after administration of candesartan cilexetil. It is more likely to occur in patients who are volume-depleted by diuretic therapy, dietary salt restriction, dialysis, diarrhea or vomiting, or undergoing surgery with anaesthesia. In these patients, because of the potential fall in blood pressure (BP), therapy should be started under close medical supervision. Similar considerations apply to patients with ischemic heart or cerebrovascular disease, in whom an excessive fall in blood pressure could result in myocardial infarction or cerebrovascular accident.

**Heart Failure**: Patients with heart failure given candesartan cilexetil commonly have some reduction in BP. Caution should be observed when initiating therapy.
Triple combination of Atacand with an ACE-inhibitor and a mineralocorticoid receptor antagonist used in heart failure is also not recommended. Use of these combinations should be under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.

**Valvular Stenosis**
There is concern on theoretical grounds that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction.

**Endocrine and Metabolism**

**Hyperkalemia**
Heart Failure: In heart failure patients treated with ATACAND, hyperkalemia may occur. During treatment with ATACAND in patients with heart failure, periodic monitoring of serum potassium is recommended, especially when taken concomitantly with ACE inhibitors and potassium-sparing diuretics such as spironolactone.

**General**

**Driving and Operating Machinery**
The effect of ATACAND on the ability to drive and use machines has not been studied, but based on its pharmacodynamic properties ATACAND is unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that dizziness or weariness may occur during treatment.

**Renal**

**Renal Impairment**
As a consequence of inhibiting the renin-angiotensin-aldosterone system (RAAS), changes in renal function have been seen in susceptible individuals. In patients whose renal function may depend on the activity of the RAAS, such as patients with bilateral renal artery stenosis, unilateral renal artery stenosis to a solitary kidney, or severe congestive heart failure, treatment with agents that inhibit this system has been associated with oliguria, progressive azotemia, and rarely, acute renal failure and/or death. In susceptible patients, concomitant diuretic use may further increase risk.

The use of ARBs, including ATACAND, or ACEIs with aliskiren-containing drugs is contraindicated in patients with moderate to severe renal impairment (GFR <60 mL/min/1.73m²) (see CONTRAINDICATIONS and DRUG INTERACTIONS, Dual Blockade of the Renin-Angiotensin-System (RAS) with ARBs, ACEIs, or aliskiren-containing drugs).

Use of ATACAND should include appropriate assessment of renal function.
Heart Failure: In heart failure patients, increases in serum creatinine may occur. Dosage reduction, and/or discontinuation of the diuretic, and/or ATACAND, and/or volume repletion may be required. Monitoring of serum creatinine is recommended during dose escalation and periodically thereafter.

Renal Transplantation
There is limited experience regarding the administration of ATACAND in adult patients with renal transplant.

Special Populations
Pregnant Women:

ATACAND is contraindicated during pregnancy (see CONTRAINDICATIONS). Drugs that act directly on the RAAS can cause fetal and neonatal morbidity and death when administered to pregnant women. When pregnancy is detected, ATACAND should be discontinued as soon as possible.

Epidemiological evidence regarding the risk of teratogenicity following exposure to ACEIs during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Given the current evidence available on the risk with ARBs, similar risks may exist for this class of drugs. Patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ARBs should be stopped immediately, and, if appropriate, alternative therapy should be started.

The use of ARBs during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia).

Animal data: Oral doses ≥ 10 mg candesartan cilexetil/kg/day administered to pregnant rats during late gestation and continued through lactation were associated with reduced survival and an increased incidence of hydronephrosis in the offspring. Candesartan cilexetil given to pregnant rabbits at an oral dose of 3 mg/kg/day caused maternal toxicity (decreased body weight and death) but, in surviving dams, had no adverse effects on fetal survival, fetal weight, or external, visceral, or skeletal development. No maternal toxicity or adverse effects on fetal development were observed when oral doses ≤1000 mg candesartan cilexetil/kg/day were administered to pregnant mice.

Nursing Women:

It is not known whether candesartan is excreted in human milk, but significant levels have been found in the milk of lactating rats. Because many drugs are excreted in human milk, and because of their potential for adversely affecting the nursing infant, a decision should be made
whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

**Pediatrics (6 to 17 years of age):**

*In utero exposure:* Infants with a history of *in utero* exposure to ARBs should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as a means of reversing hypotension and/or substituting for impaired renal function; however, limited experience with those procedures has not been associated with significant clinical benefit. Candesartan cilexetil is not removed from plasma by dialysis.

*Animal data-Heart development:* In preclinical studies in normotensive neonatal and juvenile rats, candesartan caused a reduction in relative and absolute heart weights. As in adult animals, these effects were considered to result from the pharmacological action of candesartan. At the lowest dose of 10 mg/kg, exposure to candesartan was 7-54x those found in children aged 6 to <17 years who received 16 mg of candesartan cilexetil. Since a NOAEL (no observed adverse effect level) could not be established in these studies, the safety margin for the effects on heart weight could not be determined. The clinical relevance of this finding is unknown.

*Black pediatric patients:* The antihypertensive effect of candesartan is less pronounced in Black patients compared with non-Black patients.

*Volume-depleted patients:* For children with possible intravascular volume depletion (e.g. patients treated with diuretics, particularly those with impaired renal function), ATACAND treatment should be initiated under close medical supervision and a lower starting dose should be considered (see DOSAGE AND ADMINISTRATION, Pediatrics).

*Renal impairment:* ATACAND has not been studied in children aged 6 to 17 years with renal impairment (see DOSAGE AND ADMINISTRATION, Pediatrics).

There is no experience regarding the administration of ATACAND in children aged 6 to <17 years with a renal transplant.

*Hepatic impairment:* There are no data on the effects of ATACAND in pediatric patients with hepatic impairment.

*Type 1 diabetes:* There is no experience regarding the administration of ATACAND in children aged 6 to <17 years with type 1 diabetes.

**Geriatrics (> 65 years of age):**

No overall differences in safety or effectiveness were observed between subjects >65 years of age and younger subjects. In addition, other reported clinical experience has not identified
differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

ADVERSE REACTIONS

Adverse Drug Reaction Overview

Hypertension

Adults

Potentially serious adverse reactions reported rarely with candesartan cilexetil in controlled clinical trials were syncope and hypotension.

Pediatrics (6 to 17 years of age):

The adverse reaction profile of ATACAND as a treatment for hypertension in pediatric patients appeared similar to that seen in adults. However, the frequency of all adverse events (AEs) seemed higher.

Sinus arrhythmia, which was not reported in adults, was observed in 2.9% and 2.0% of pediatric patients taking ATACAND for 4 weeks and 1 year, respectively.

Heart Failure

Severe adverse reactions most commonly seen in adult heart failure patients taking candesartan cilexetil in controlled clinical trials were hypotension, hyperkalemia and renal impairment.

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Hypertension
**Adults**

ATACAND (candesartan cilexetil) was evaluated for safety in >8700 patients treated for hypertension, including 677 treated for ≥6 months and 626 for ≥1 year. Of these, 8694 were treated with candesartan cilexetil monotherapy in controlled clinical trials.

In placebo-controlled clinical trials, discontinuation due to AEs occurred in 2.9% and 2.7% of patients treated with ATACAND monotherapy and placebo, respectively.

In the double blind, placebo-controlled trials, the overall incidence of AEs showed no association with dose, age or gender. In these trials, the following AEs reported with ATACAND occurred in ≥ 1% of patients, regardless of drug relationship:

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Adverse events that occurred in ≥1% of patients regardless of drug relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ATACAND n = 1388 (%)</td>
</tr>
<tr>
<td><strong>Body as a Whole</strong></td>
<td></td>
</tr>
<tr>
<td>back pain</td>
<td>3.2</td>
</tr>
<tr>
<td>fatigue</td>
<td>1.5</td>
</tr>
<tr>
<td>abdominal pain</td>
<td>1.5</td>
</tr>
<tr>
<td>peripheral edema</td>
<td>1.0</td>
</tr>
<tr>
<td><strong>Digestive</strong></td>
<td></td>
</tr>
<tr>
<td>nausea</td>
<td>1.9</td>
</tr>
<tr>
<td>diarrhea</td>
<td>1.5</td>
</tr>
<tr>
<td>vomiting</td>
<td>1.0</td>
</tr>
<tr>
<td><strong>Nervous/Psychiatric</strong></td>
<td></td>
</tr>
<tr>
<td>headache</td>
<td>10.4</td>
</tr>
<tr>
<td>dizziness</td>
<td>2.5</td>
</tr>
<tr>
<td><strong>Respiratory</strong></td>
<td></td>
</tr>
<tr>
<td>upper respiratory infection</td>
<td>5.1</td>
</tr>
<tr>
<td>coughing</td>
<td>1.6</td>
</tr>
<tr>
<td>influenza-like symptoms</td>
<td>1.5</td>
</tr>
<tr>
<td>pharyngitis</td>
<td>1.1</td>
</tr>
<tr>
<td>bronchitis</td>
<td>1.0</td>
</tr>
<tr>
<td>rhinitis</td>
<td>1.0</td>
</tr>
</tbody>
</table>
Clinical trials in which doses ≤32 mg were administered did not result in a significant increase in any of the AEs listed above.

**Pediatrics (6 to 17 years of age)**

ATACAND was evaluated for safety in 240 hypertensive pediatric patients aged 6 to 17 years during a 4-week placebo-controlled clinical trial and in 235 pediatric patients in the 1-year open-label extension study. A total of 213 pediatric patients from the placebo-controlled trial enrolled in the open-label study. There were 178 patients who were treated for ≥1 year.

The adverse reaction profile of ATACAND in pediatric patients appeared similar to that seen adults. However, the frequency of all AEs seemed higher.

In the placebo-controlled clinical trial, the most common AEs (≥3% of patients) were cough, dizziness, headache, pharyngolaryngeal pain and upper respiratory tract infection. Dizziness was the most common drug-related AE.

In the open-label extension study, 3 out of 240 pediatric patients aged 6 to 17 years experienced worsening renal disease. The association between candesartan and the exacerbation of the underlying condition could not be excluded.

Sinus arrhythmia, which was not reported in adults, was observed in 2.9% and 2.0% of pediatric patients taking ATACAND for 4 weeks and 1 year, respectively.

**Heart Failure**

The AE profile of ATACAND in adult heart failure patients was consistent with the pharmacology of the drug and the health status of the patients. In the CHARM-Alternative and CHARM-Added studies comparing ATACAND in total daily doses ≤32 mg once daily to placebo, 23.2% of ATACAND and 18.4% of placebo patients discontinued the treatment due to AEs.

In these trials, the following AEs reported with ATACAND occurred in ≥1% of patients and with higher frequency than placebo, regardless of drug relationship.
### Table 2

Adverse events reported in CHARM-Alternative and CHARM-Added and occurring with frequency of ≥ 1% regardless of drug relationship

<table>
<thead>
<tr>
<th></th>
<th>ATACAND n=2289 (%)</th>
<th>Placebo n=2287 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Body as a Whole</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>1.4</td>
<td>0.9</td>
</tr>
<tr>
<td><strong>Cardiovascular Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypotension</td>
<td>20.9</td>
<td>11.0</td>
</tr>
<tr>
<td>Syncope</td>
<td>3.3</td>
<td>3.2</td>
</tr>
<tr>
<td>Coronary artery disorder</td>
<td>4.2</td>
<td>3.5</td>
</tr>
<tr>
<td>Cardiac arrest</td>
<td>1.3</td>
<td>1.1</td>
</tr>
<tr>
<td><strong>Blood disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anemia</td>
<td>2.8</td>
<td>2.3</td>
</tr>
<tr>
<td><strong>Gastro-Intestinal System disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>2.4</td>
<td>1.1</td>
</tr>
<tr>
<td>Gastroenteritis</td>
<td>1.1</td>
<td>0.7</td>
</tr>
<tr>
<td><strong>Liver and Biliary System Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholelithiasis</td>
<td>1.1</td>
<td>0.9</td>
</tr>
<tr>
<td><strong>Metabolic and Nutritional Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperkalemia</td>
<td>7.6</td>
<td>2.6</td>
</tr>
<tr>
<td>Dehydration</td>
<td>2.5</td>
<td>1.3</td>
</tr>
<tr>
<td>Nonprotein nitrogen increased</td>
<td>1.3</td>
<td>0.3</td>
</tr>
<tr>
<td>Uremia</td>
<td>1.1</td>
<td>0.5</td>
</tr>
<tr>
<td>Gout</td>
<td>1.0</td>
<td>0.9</td>
</tr>
<tr>
<td><strong>Muscuro-Skeletal System Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthrosis</td>
<td>1.2</td>
<td>1.0</td>
</tr>
<tr>
<td><strong>Nervous System Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>3.4</td>
<td>2.1</td>
</tr>
<tr>
<td>Headache</td>
<td>1.0</td>
<td>0.7</td>
</tr>
<tr>
<td><strong>Urinary System Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal function abnormal</td>
<td>14.3</td>
<td>7.2</td>
</tr>
<tr>
<td>Renal failure acute</td>
<td>3.0</td>
<td>1.8</td>
</tr>
</tbody>
</table>
**Less Common Clinical Trial Adverse Drug Reactions (< 1%)**

**Hypertension**

The following AEs were reported at an incidence of < 1% in controlled clinical trials (in >1 patient, with higher frequency than placebo):

- **Body as a Whole:** allergy, asthenia, pain, syncope.
- **Cardiovascular:** angina pectoris, circulatory failure, flushing, hypotension, myocardial infarction, peripheral ischemia, thrombophlebitis.
- **Central and Peripheral Nervous System:** hypertonia, hypoesthesia, paresthesia, vertigo.
- **Gastrointestinal:** constipation, dry mouth, dyspepsia, toothache.
- **Hearing:** tinnitus.
- **Metabolic and Nutritional:** diabetes mellitus, hyperkalemia, hyponatremia.
- **Musculoskeletal:** arthritis, arthropathy, myalgia, myopathy, skeletal pain, tendon disorder.
- **Blood:** anemia, epistaxis.
- **Psychiatric:** depression, impotence, neurosis.
- **Reproductive:** menopausal symptoms.
- **Resistance Mechanism:** otitis.
- **Respiratory:** laryngitis.
- **Skin:** eczema, pruritus, rash, skin disorder, sweating, (rarely) urticaria.
- **Urinary:** abnormal urine, cystitis.
- **Vision:** conjunctivitis.

AEs reported at a rate >1% but at about the same or greater incidence in patients receiving placebo, in studies using daily doses >16 mg: albuminuria, arthralgia, chest pain and sinusitis.

Other AEs reported at an incidence of ≥0.5% from >3200 patients treated worldwide include anxiety, dyspnea, fever, gastroenteritis, hematuria, hyperglycemia, hypertriglyceridemia, hyperuricemia, increased creatinine phosphokinase, palpitation, somnolence and tachycardia.

**Heart Failure**

The following listed AEs occurred in <1% of patients treated with ATACAND but in ≥2 patients and with more frequent occurrence in the ATACAND group than in the placebo group (CHARM-Alternative and CHARM-Added).

- **Skin and Appendages Disorders:** angioedema, pruritus, rash.
- **Liver and Biliary System Disorders:** hepatic function abnormal.
- **White Cell and Resistance Disorders:** granulocytopenia, leukopenia.
Abnormal Hematologic and Clinical Chemistry Findings

Laboratory Test Findings

Hypertension

In controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with administration of ATACAND.

*Liver Function Tests:* In controlled clinical trials, elevations of AST and ALT (> 3x the upper limit of normal) occurred in 0.3% and 0.5%, respectively, of patients treated with ATACAND monotherapy compared to 0.2% and 0.4%, respectively, of patients receiving placebo.

*Serum Potassium:* A small increase (mean increase of 0.1 mEq/L) was observed in hypertensive patients treated with ATACAND alone but was rarely of clinical importance.

*Creatinine, Blood Urea Nitrogen, and Sodium:* Infrequent minor increases in blood urea nitrogen (BUN) and serum creatinine as well as decreases in sodium were observed.

*Hemoglobin and Hematocrit:* Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.2 g/dL and 0.5 volume %, respectively) were observed in patients treated with ATACAND alone but were rarely of clinical importance. Anemia, leukopenia and thrombocytopenia were associated with withdrawal of 1 patient each from clinical trials.

*Hyperuricemia:* Hyperuricemia was rarely found (0.6% of patients treated with ATACAND and 0.5% of patients treated with placebo).

Heart Failure

Increases in serum creatinine, potassium and urea, and decreases in hemoglobin and hematocrit were observed.

Post-Market Adverse Drug Reactions

In post-marketing experience, the following have been reported in patients treated with ATACAND:

**Blood and lymphatic disorders:** thrombocytopenia

**Cardiac disorders:** atrial fibrillation, bradycardia, cardiac failure, palpitations

**Digestive:** abnormal hepatic function and hepatitis

**Gastrointestinal disorders:** pancreatitis

**General disorders and administration site conditions:** chest pain, malaise, sudden death

**Hematologic:** agranulocytosis, leukopenia and neutropenia
**Immunologic:** angioedema, involving swelling of the face, lips and/or tongue, hypersensitivity

**Infections and infestations:** pneumonia

**Investigations:** blood creatinine increased, fall

**Metabolic and Nutritional Disorders:** hyperkalemia and hyponatremia

**Musculoskeletal System:** muscle pain, muscle weakness, myositis and rhabdomyolysis

**Nervous system disorders:** cerebrovascular accident, loss of consciousness, presyncope

**Psychiatric disorders:** confusional state

**Respiratory System Disorders:** cough, pulmonary edema

**Skin and Appendages Disorders:** pruritus, rash and urticarial

**Urogenital System:** renal impairment, including renal failure in elderly susceptible patients (see WARNINGS AND PRECAUTIONS, Renal, Renal Impairment for definition of susceptible patients)

---

**DRUG INTERACTIONS**

**Overview**

*In vitro* studies indicate that cytochrome P450 isoenzyme CYP 2C9 is involved in the biotransformation of candesartan to its inactive metabolite. Based on *in vitro* data, no interaction would be expected to occur *in vivo* with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4.

Interaction studies have only been performed in adults.

**Drug-Drug Interactions**

*The drugs listed in Table 3 are based on either drug interaction case reports or studies or potential interactions due to the expected magnitude and seriousness of the interaction (i.e. those identified as contraindicated).*
<table>
<thead>
<tr>
<th>Proper Name</th>
<th>Reference</th>
<th>Effect</th>
<th>Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agents Increasing Serum Potassium</td>
<td>T</td>
<td>ATACAND decreases the production of aldosterone.</td>
<td>Potassium-sparing diuretics or potassium supplements or other drugs that may increase potassium levels (e.g., heparin, co-trimoxazole) should be given only for documented hypokalemia and with frequent monitoring of serum potassium. Potassium-containing salt substitute should also be used with caution.</td>
</tr>
<tr>
<td>Diuretics</td>
<td>CT</td>
<td>Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ATACAND.</td>
<td>The possibility of symptomatic hypotension with the use of ATACAND can be minimized by discontinuing the diuretic prior to initiation of treatment and/or lowering the initial dose of ATACAND (see WARNINGS AND PRECAUTIONS, Cardiovascular, Hypotension and DOSAGE AND ADMINISTRATION). No drug interactions of clinical significance have been identified with thiazide diuretics in patients treated with ≤25 mg hydrochlorothiazide with 16 mg ATACAND for 8 weeks.</td>
</tr>
</tbody>
</table>
Table 3  Established or Potential Drug-Drug Interactions with ATACAND (candesartan cilexetil)

<table>
<thead>
<tr>
<th>Proper Name</th>
<th>Reference</th>
<th>Effect</th>
<th>Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Digoxin</td>
<td>CT</td>
<td>Combination treatment with candesartan cilexetil and digoxin in healthy volunteers had no effect on AUC or $C_{\text{max}}$ values for candesartan compared to candesartan cilexetil alone.</td>
<td>No dosage adjustment.</td>
</tr>
<tr>
<td>Dual blockade of the Renin-Angiotensin System (RAS) with ARBs, ACEIs or aliskiren-containing drugs</td>
<td>CT</td>
<td>Clinical trial data has shown that dual blockade of the renin-angiotensin-system (RAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAS-acting agent.</td>
<td>Dual blockade of the RAS with ARBs or ACEIs and aliskiren-containing drugs is contraindicated in patients with diabetes and/or renal impairment (see CONTRAINDICATIONS). The combined use of ARBs, ACEIs or aliskiren-containing drugs is generally not recommended [see WARNINGS AND PRECAUTIONS, Dual Blockade of the Renin-Angiotensin-System (RAS)].</td>
</tr>
<tr>
<td>Enalapril</td>
<td>CT</td>
<td>While there is no clinically relevant interaction between candesartan and enalapril, patients with renal impairment showed a higher exposure to both drugs. This is consistent with the known pharmacokinetics of</td>
<td>Dosage may need to be adjusted based on the response of the patient.</td>
</tr>
<tr>
<td>Proper Name</td>
<td>Reference</td>
<td>Effect</td>
<td>Clinical Comment</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>-----------</td>
<td>------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Lithium Salts</td>
<td>CT</td>
<td>As with other drugs which eliminate sodium, lithium clearance may be reduced.</td>
<td>Serum lithium levels should be monitored carefully if lithium salts are to be administered.</td>
</tr>
<tr>
<td>Non-steroidal anti-inflammatory drugs (NSAIDs)</td>
<td>CT</td>
<td>Attenuation of the antihypertensive effect may occur when simultaneously administering ARBs and NSAIDs; i.e. selective COX-2 inhibitors, acetylsalicylic acid and non-selective NSAIDs.</td>
<td>The combination ARBs and NSAIDs should be administered with caution, especially in older patients and in volume depleted patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and periodically thereafter.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Warfarin</td>
<td>CT</td>
<td>When candesartan cilexetil was administered at 16 mg</td>
<td>No dosage adjustment.</td>
</tr>
</tbody>
</table>

Table 3  Established or Potential Drug-Drug Interactions with ATACAND (candesartan cilexetil)
Table 3  Established or Potential Drug-Drug Interactions with ATACAND (candesartan cilexetil)

<table>
<thead>
<tr>
<th>Proper Name</th>
<th>Reference</th>
<th>Effect</th>
<th>Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other</td>
<td></td>
<td>once daily under steady state conditions, no pharmacodynamic effect on prothrombin time was demonstrated in subjects stabilized on warfarin.</td>
<td>No dosage adjustment.</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td>No significant drug interactions have been reported with glyburide, nifedipine or oral contraceptives co-administered with candesartan cilexetil to healthy volunteers.</td>
<td>No dosage adjustment.</td>
</tr>
</tbody>
</table>

Legend: C= Case Study; CT= Clinical Trial; T= Theoretical

**Drug-Food Interactions**
ATACAND may be taken with or without food (see DOSAGE AND ADMINISTRATION).

**DOSAGE AND ADMINISTRATION**

**Dosing Considerations**
The dosage of ATACAND (candesartan cilexetil) must be individualized.

**Recommended Dose and Dosage Adjustment**
ATACAND should be taken once daily, at approximately the same time each day, with or without food.

**Hypertension**

**Adults**
Initiation of therapy requires consideration of recent antihypertensive treatment, the extent of BP elevation, salt restriction, and other pertinent clinical factors. The dosage of other antihypertensive agents used with ATACAND may need to be adjusted. BP response is dose related over the range of 4 - 32 mg.

The recommended initial dose of ATACAND is 16 mg, once daily when used as monotherapy. Total daily doses of ATACAND should range from 8- 32 mg. Doses >32 mg...
do not appear to have a greater effect on BP reduction, and there is relatively little experience with such doses. Most of the antihypertensive effect is present within 2 weeks and the maximal BP reduction is generally obtained within 4 weeks. For patients with possible depletion of intravascular volume (e.g. patients treated with diuretics, particularly those with impaired renal function) consideration should be given to administration of a lower dose. If BP is not controlled by ATACAND alone, a thiazide diuretic may be added (See DRUG INTERACTIONS, Drug-Drug Interactions, Diuretics).

**Concomitant Diuretic Therapy**

In patients receiving diuretics, ATACAND therapy should be initiated with caution, since these patients may be volume-depleted and thus more likely to experience hypotension following initiation of additional antihypertensive therapy.

Whenever possible, all diuretics should be discontinued 2-3 days prior to the administration of ATACAND, to reduce the likelihood of hypotension (see WARNINGS AND PRECAUTIONS, Cardiovascular, Hypotension). If this is not possible because of the patient's condition, ATACAND should be administered with caution and BP monitored closely. Thereafter, the dosage should be adjusted according to the individual response of the patient.

**Hepatic Impairment**

*Mild to moderate hepatic impairment:* No dosage adjustment is necessary.

*Severe hepatic impairment and/or cholestasis:* There is only limited experience. In patients with severely impaired hepatic function, a lower initial dose of 4 mg should be considered.

**Renal Impairment**

*Mild renal impairment:* No dosage adjustment is necessary

*Moderate or severe renal impairment or patients undergoing dialysis:* A lower initial dose of 4 mg should be considered.

**Geriatrics (> 65 years of age)**

No dosage adjustment is necessary for elderly patients. As greater sensitivity of some older patients cannot be ruled out, appropriate caution is recommended (see WARNINGS AND PRECAUTIONS, Geriatrics).

**Pediatrics (6 to 17 years of age)**

- Patients weighing <50 kg: The recommended starting dose is 4 mg once daily.
In some patients whose BP is not adequately controlled, the dose can be increased to 8 mg once daily.
The maximum dose is 8 mg once daily

- Patients weighing ≥ 50 kg: The recommended starting dose is 8 mg once daily.
  In some patients whose BP is not adequately controlled, the dose can be increased to 16 mg once daily.
The maximum dose is 16 mg once daily.

The dose should be adjusted according to BP response.

Most of the antihypertensive effect is attained within 4 weeks.

Doses >32 mg have not been studied in pediatric patients.

For children with possible intravascular volume depletion (e.g. patients treated with diuretics, particularly those with impaired renal function), ATACAND treatment should be initiated under close medical supervision and a lower starting dose than the general starting dose above should be considered (see WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics).

**Heart Failure**

**Adults**

The usual recommended initial dose for treating heart failure is 4 mg once daily. The target dose is 32 mg once daily which is achieved by doubling the dose at approximately 2 week intervals, as tolerated by the patient. ATACAND can be administered with other heart failure treatments including ACEIs, beta-blockers, diuretics, digoxin, and/or spironolactone.

No initial dose adjustment is necessary for elderly patients or in patients with renal or hepatic impairment.

**Pediatrics (6 to 17 years of age)**

The safety and efficacy of ATACAND in the treatment of heart failure have not been established in children and adolescents <18 years of age.

**Missed Dose**

If a patient misses a dose of ATACAND and remembers within 12 hours, the patient should take the dose as soon as possible and then go back to the regular schedule. If it is more than 12 hours after the patient remembers, they should not take the missed dose; the next dose should be taken on time.
A double dose of ATACAND should never be taken to make up for a missed dose.

**OVERDOSAGE**

For management of a suspected drug overdose, contact your regional Poison Control Centre.

Limited data are available in regard to overdosage in humans. The most likely manifestations of overdosage would be hypotension, dizziness and tachycardia; bradycardia could occur from reflex parasympathetic (vagal) stimulation. In case reports detailing overdosage [≤672 mg ATACAND (candesartan cilexetil)] in adults, patient recovery was uneventful.

If symptomatic hypotension should occur, supportive treatment should be instituted and vital signs monitored. The patient should be placed supine with the legs elevated. If this is not sufficient, plasma volume should be increased by infusion of, for example, isotonic saline solution. Sympathomimetic drugs may also be administered if the above-mentioned measures are not sufficient. Candesartan cilexetil is not removed from the plasma by hemodialysis.

**ACTION AND CLINICAL PHARMACOLOGY**

**Mechanism of Action**

ATACAND (candesartan cilexetil) antagonizes angiotensin II by blocking the angiotensin type one (AT\textsubscript{1}) receptor. Angiotensin II is the primary vasoactive hormone of RAAS with effects that include vasoconstriction, stimulation of aldosterone secretion and renal reabsorption of sodium.

Candesartan cilexetil, a prodrug, is rapidly converted to the active drug, candesartan, during absorption from the gastrointestinal tract.

Candesartan blocks the vasoconstrictor and aldosterone secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT\textsubscript{1} receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis. There is also an AT\textsubscript{2} receptor found in many tissues, but it plays no known role in cardiovascular homeostasis to date. Candesartan has a much greater affinity (> 10,000 fold) for the AT\textsubscript{1} receptor than for the AT\textsubscript{2} receptor. The strong bond between candesartan and the AT\textsubscript{1} receptor is a result of tight binding to and slow dissociation from the receptor.

Candesartan does not inhibit ACE, also known as kininase II, the enzyme that converts angiotensin I to angiotensin II and degrades bradykinin, nor does it bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.

**Pharmacodynamics**

Candesartan inhibits the pressor effects of angiotensin II infusion in a dose dependent manner. After 1 week of once-daily dosing of 8 mg candesartan cilexetil, the pressor effect was
inhibited by approximately 90% at peak (4-8 hours after dosing) with approximately 50% inhibition persisting at 24 hours.

Plasma concentrations of angiotensin I, angiotensin II, and plasma renin activity, increased in a dose-dependent manner after single and repeated administration of candesartan cilexetil to adult healthy subjects, hypertensive and heart failure patients. A decrease in the plasma concentration of aldosterone was observed when 32 mg of candesartan cilexetil was administered to hypertensive patients.

**Pharmacokinetics**

**Absorption:** Following oral administration of candesartan cilexetil as a tablet, the absolute bioavailability of candesartan is estimated to be approximately 15%. After tablet ingestion, the peak serum concentration ($C_{\text{max}}$) is reached after 3-4 hours. Food does not affect the bioavailability of candesartan after candesartan cilexetil administration.

**Distribution:** The volume of distribution of candesartan is 0.13 L/kg. Candesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells. The protein binding is constant at candesartan plasma concentrations well above the range achieved with recommended doses. In rats, it has been demonstrated that candesartan does cross the blood-brain barrier. It has also been demonstrated in rats that candesartan passes across the placental barrier and is distributed in the fetus.

**Metabolism:** Candesartan cilexetil is rapidly and completely bioactivated to candesartan by ester hydrolysis during absorption from the gastrointestinal tract. It undergoes minor hepatic metabolism by O-deethylation to an inactive metabolite. *In vitro* studies indicate that cytochrome P450 isozyme CYP 2C9 is involved in the biotransformation of candesartan to its inactive metabolite. Based on *in vitro* data, no interaction would be expected to occur *in vivo* with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4.

**Excretion:** Total plasma clearance of candesartan is 0.37 mL/min/kg, with a renal clearance of 0.19 mL/min/kg. Candesartan is mainly excreted unchanged in urine and feces (via bile). When candesartan cilexetil is administered orally, about 26% of the dose is excreted as candesartan in urine. Following an oral dose of $^{14}$C-labeled candesartan cilexetil, approximately 33% of radioactivity is recovered in urine and approximately 67% in feces. Following an intravenous (iv) dose of $^{14}$C-labeled candesartan, approximately 59% of radioactivity is recovered in urine and approximately 36% in feces. Biliary excretion contributes to the elimination of candesartan. The elimination half-life of candesartan is approximately 9 hours. After single and repeated administration, the pharmacokinetics of candesartan are linear for oral doses ≤32 mg. Candesartan and its inactive metabolite do not accumulate in serum upon repeated once-daily dosing.

**Special Populations and Conditions**

**Geriatrics:** The plasma concentration of candesartan was higher in the elderly (≥ 65 years old) ($C_{\text{max}}$ was approximately 50% higher, and AUC was approximately 80% higher)
compared to younger subjects administered the same dose. The pharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite did not accumulate in the serum of these subjects upon repeated, once-daily administration.

**Pediatrics (6 to 17 years of age):** Pediatric (6 to 17 years of age) hypertensive patients that received a 16 mg dose of candesartan cilexetil had exposure similar to adults given the same dose. The pharmacokinetics (Cmax and AUC) were not modified by age, sex or body weight. From the dose-ranging studies of candesartan cilexetil, there was a dose related increase in plasma candesartan concentrations.

ATACAND pharmacokinetics have not been determined in children and adolescent (6 to 17 years of age) with renal insufficiency.

**Gender:** No gender-related differences in the pharmacokinetics of candesartan have been observed.

**Hepatic Insufficiency:**
Mild to moderate hepatic impairment: There was an increase in the AUC of candesartan of approximately 20%. There was no drug accumulation in plasma in these patients.

Moderate to severe hepatic impairment: Cmax and AUC increased up to 5x in a very small group administered a single dose of 16 mg candesartan (see DOSAGE AND ADMINISTRATION, Hepatic Impairment).

**Renal Insufficiency:**
Mild to moderate renal impairment (GFR 31-60 mL/min/1.73m^2): Cmax and AUC of candesartan increased by 40-60% and 50-90%, respectively, but t1/2 was not altered, compared to patients with normal renal function (GFR >60 mL/min/1.73m^2) during repeated dosing. There was no drug accumulation in plasma.

Severe renal impairment (GFR 15-30 mL/min/1.73m^2): The increases in Cmax and AUC were 40-60% and 110%, respectively. The terminal t1/2 of candesartan was approximately 2x in patients with severe renal impairment, and these changes resulted in some accumulation in plasma.

Patients undergoing hemodialysis: The pharmacokinetics of candesartan were similar to those in patients with severe renal impairment (see DOSAGE AND ADMINISTRATION, Renal Impairment).

**STORAGE AND STABILITY**
Store at 15-30°C.
DOSAGE FORMS, COMPOSITION AND PACKAGING

Dosage Forms
ATACAND (candesartan cilexetil) is available in tablets of 4 mg, 8 mg, 16 mg and 32 mg.

Composition

Medicinal ingredient: candesartan cilexetil 4 mg, 8 mg, 16 mg or 32 mg.

Nonmedicinal ingredients: calcium carboxymethylcellulose, hydroxypropyl cellulose, iron oxide (except 4 mg tablets), lactose, magnesium stearate, maize starch and polyethylene glycol.

Packaging

ATACAND 4 mg tablets: White, biconvex, circular tablets with a score and marked A CF on one side and marked 004 on the other side, available in blister packs of 30 tablets.

ATACAND 8 mg tablets: Light pink, biconvex, circular tablets with a score and marked A CG on one side and marked 008 on the other side, available in blister packs of 30 tablets.

ATACAND 16 mg tablets: Pink, biconvex, circular tablets with a score and marked A CH on one side and marked 016 on the other side, available in blister packs of 30 tablets.

ATACAND 32 mg tablets: Pink, biconvex, circular tablets with a score and marked A CL on one side and marked 032 on the other side, available in blister packs of 30 tablets.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper Name: candesartan cilexetil

Chemical Name: \((\pm)-1-(\text{Cyclohexyloxycarbonyloxy})\text{ethyl-2-ethoxy-1-}
[[2'(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-
benzimidazole-7-carboxylate\)

Molecular Formula and Molecular Mass: \(C_{33}H_{34}N_6O_6\) 610.67

Structural Formula:

![Structural formula of candesartan cilexetil]

Physicochemical Properties:

Description:
Candesartan cilexetil is a white to off-white powder. Solubility in benzyl alcohol: 205 g/L. Solubility in water: < 5x10^{-5} g/L.

Melting Point:
163°C with decomposition.

<table>
<thead>
<tr>
<th>Partition Coefficient (K at 20°C)</th>
<th>pH of Aqueous Layer</th>
<th>Ethyl Ether</th>
<th>1-Octanol</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1.1</td>
<td>&gt; 1000</td>
<td>&gt; 1000</td>
</tr>
<tr>
<td></td>
<td>6.9</td>
<td>&gt; 1000</td>
<td>&gt; 1000</td>
</tr>
<tr>
<td></td>
<td>8.9</td>
<td>141</td>
<td>&gt; 1000</td>
</tr>
</tbody>
</table>

\[
K = \frac{\text{Concentration of Candesartan Cilexetil in the organic layer}}{\text{Concentration of Candesartan Cilexetil in the aqueous layer}}
\]
CLINICAL TRIALS

Hypertension

Adults

ATACAND (candesartan cilexetil) causes a dose-dependent reduction in arterial blood pressure (BP). Systemic peripheral resistance is decreased, while heart rate, stroke volume and cardiac output are not significantly affected. No first dose hypotension was observed during controlled clinical trials with ATACAND.

Most of the antihypertensive effect was seen within 2 weeks of initial dosing, and the full effect in 4 weeks. With once-daily dosing, BP effect was maintained over 24 hours with trough to peak ratios of BP effect generally >80%. Candesartan cilexetil had an additional BP lowering effect when added to hydrochlorothiazide.

The antihypertensive effect was similar in men and women and in patients <65 and ≥65 years. Candesartan was effective in reducing BP regardless of race, although the effect was somewhat less in Blacks (usually a low-renin population) than in Caucasians.

In long-term studies of ≤1 year, the antihypertensive effectiveness of candesartan cilexetil was maintained and there was no rebound after abrupt withdrawal.

ATACAND reduces urinary albumin excretion in patients with type II diabetes mellitus, hypertension and microalbuminuria. In a 12-week study of 161 mildly hypertensive patients with type II diabetes mellitus, ATACAND 8-16 mg had no effect on mean A1c.

Pediatrics (6 to 17 years of age)

The antihypertensive effects of candesartan were evaluated in hypertensive children aged 6 to < 17 years in a randomised, double-blind, multicentre, 4-week dose-ranging study. A total of 240 patients were randomised to receive either placebo or low (2/4 mg), medium (8/16 mg) or high (16/32 mg) doses of candesartan cilexetil in a ratio of 1:2:2:2. For children who weighed < 50 kg, the doses of candesartan cilexetil were 2, 8 or 16 mg once daily. For children who weighed ≥50 kg, the candesartan cilexetil doses were 4, 16 or 32 mg once daily. Of those enrolled, 47% were Black patients and 29% were female; mean age ± SD was 12.9 ± 2.6 years. In addition, the majority of patients were ≥95th percentile for body mass index (BMI) (68.8%) and suffered from primary hypertension (90.2%).

The placebo subtracted effect at trough for sitting SBP/ sitting DBP for the different doses ranged from 4.9/3.0 to 7.5/6.2 mm Hg.

In children aged 6 to < 17 years, there was a trend for a lesser effect on BP in Black patients compared to non-Black patients. This was similar to what was observed in adults with hypertension.
Comparative Effects

The antihypertensive efficacy of candesartan cilexetil and losartan potassium have been compared at their once daily maximum doses, 32 mg and 100 mg, respectively, in patients with mild to moderate essential hypertension. Candesartan cilexetil lowered systolic and diastolic blood pressure by 2 to 3 mm Hg on average more than losartan potassium when measured at the time of either peak or trough effect. Both agents were well tolerated.

Heart Failure

In heart failure patients, ATACAND administration resulted in a dose-related increase in plasma renin activity and angiotensin II concentration, and a decrease in aldosterone levels.

The effects of ATACAND on mortality and hospitalization due to Congestive Heart Failure (CHF) were evaluated in 2 studies, CHARM-Alternative and CHARM-Added. These were multinational, placebo-controlled, double-blind studies in patients with New York Heart Association (NYHA) functional class II to class IV CHF. Only 3% of the patient population within each of these studies had Class IV CHF as a baseline characteristic. CHARM-Alternative (n=2,028) included patients with a LVEF ≤ 40% not treated with ACE inhibitors because of intolerance. CHARM-Added (n=2,548) was carried out in patients with LVEF ≤ 40% tolerant of ACE inhibitors and treated with ACE inhibitors. In these studies patients were randomised to receive either placebo or ATACAND in addition to standard therapy. ATACAND was titrated from 4 mg or 8 mg once daily to 32 mg once daily (mean 23 mg) or the highest tolerated dose. Patients were followed for ≤4 years, with a median of 40 months. Standard therapy included diuretics, β-blockers, ACE inhibitors, digoxin and spironolactone.

The primary composite endpoint of cardiovascular (CV) mortality or first CHF hospitalisation was significantly reduced with ATACAND in comparison with placebo in CHARM-Alternative (hazard ratio (HR) 0.77, 95% CI 0.67-0.89, p<0.001) and in CHARM-Added (HR 0.85, 95% CI 0.75-0.96, p=0.011). This corresponded to a relative risk reduction of 23% and 15%, respectively.

Table 4 CHARM – Alternative: Primary Endpoint and its Components

<table>
<thead>
<tr>
<th>Endpoint (time to first event)</th>
<th>ATACAND (n=1013)</th>
<th>Placebo (n=1015)</th>
<th>Hazard Ratio (95% CI)</th>
<th>p-value (logrank)</th>
<th>Relative Risk Reduction</th>
<th>Absolute Risk Reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>CV death or CHF hospitalisation</td>
<td>334</td>
<td>406</td>
<td>0.77 (0.67-0.89)</td>
<td>&lt;0.001</td>
<td>23%</td>
<td>7.0%</td>
</tr>
<tr>
<td>CV death</td>
<td>219</td>
<td>252</td>
<td>0.85 (0.71-1.02)</td>
<td>0.072</td>
<td>15%</td>
<td>3.2%</td>
</tr>
<tr>
<td>CHF hospitalisation</td>
<td>207</td>
<td>286</td>
<td>0.68 (0.57-0.81)</td>
<td>&lt;0.001</td>
<td>32%</td>
<td>7.7%</td>
</tr>
</tbody>
</table>
NOTE: In CHARM-Alternative, 14 patients needed to be treated for the duration of the study (median 34 months) to prevent 1 patient from dying of a CV event or being hospitalised for treatment of HF.

Table 5  
CHARM – Added: Primary Endpoint and its Components

<table>
<thead>
<tr>
<th>Endpoint (time to first event)</th>
<th>ATACAND (n=1276)</th>
<th>Placebo (n=1272)</th>
<th>Hazard Ratio (95% CI)</th>
<th>p-value (logrank)</th>
<th>Relative Risk Reduction</th>
<th>Absolute Risk Reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>CV death or CHF hospitalisation</td>
<td>483</td>
<td>538</td>
<td>0.85 (0.75-0.96)</td>
<td>0.011</td>
<td>15%</td>
<td>4.4%</td>
</tr>
<tr>
<td>CV death</td>
<td>302</td>
<td>347</td>
<td>0.84 (0.72-0.98)</td>
<td>0.029</td>
<td>16%</td>
<td>3.6%</td>
</tr>
<tr>
<td>CHF hospitalisation</td>
<td>309</td>
<td>356</td>
<td>0.83 (0.71-0.96)</td>
<td>0.013</td>
<td>17%</td>
<td>3.8%</td>
</tr>
</tbody>
</table>

NOTE: In CHARM-Added, 23 patients needed to be treated for the duration of the study (median 41 months) to prevent 1 patient from dying of a CV event or being hospitalised for treatment of HF.

The secondary composite endpoint of all-cause mortality or first CHF hospitalisation was also significantly reduced with ATACAND in CHARM-Alternative (HR 0.80, 95% CI 0.70-0.92, p=0.001) and CHARM-Added (HR 0.87, 95% CI 0.78-0.98, p=0.021). This corresponded to a relative risk reduction of 20% and 13%, respectively.

Treatment with ATACAND resulted in improved NYHA functional class in CHARM-Alternative (p=0.008) and CHARM-Added (p=0.020).

Comparative Bioavailability Studies

The bioequivalence of 1 candesartan cilexetil 32 mg tablet and 2 candesartan cilexetil 16 mg tablets was established in a single-blind, single-dose, randomised, 2-period crossover study in 50 (33 M/17 F) healthy volunteers. During each treatment period, subjects received candesartan cilexetil as a single oral dose of either 1 x 32 mg or 2 x 16 mg. The 2 treatment periods were separated by a washout of 6-14 days. The 90% confidence intervals for the ratio of 1 candesartan cilexetil 32 mg tablet versus 2 candesartan cilexetil 16 mg tablets for AUC$_{0-inf}$ and C$_{max}$ fell entirely within the equivalence range of 80-125%.

Table 6  
Pharmacokinetic comparison of ATACAND (candesartan cilexetil) 1 x 32 mg tablet versus 2 x 16 mg tablets

<table>
<thead>
<tr>
<th>Candesartan</th>
<th>(32 mg dose as either 1 x 32 mg or 2 x 16 mg)</th>
<th>From measured data, uncorrected for potency</th>
<th>Geometric Mean$^a$</th>
<th>Arithmetic Mean (CV%)</th>
</tr>
</thead>
</table>
### Table 7 Acute toxicity

<table>
<thead>
<tr>
<th>Route</th>
<th>Species</th>
<th>Sex</th>
<th>LD₅₀ Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>intraperitoneal</td>
<td>mouse</td>
<td>female male</td>
<td>891 807</td>
</tr>
<tr>
<td>intraperitoneal</td>
<td>rat</td>
<td>female male</td>
<td>1210 940</td>
</tr>
</tbody>
</table>

**DETAILED PHARMACOLOGY**

**Animal Pharmacology**

In isolated rabbit aorta helical strips, candesartan at $3 \times 10^{-11}$ to $10^{-9}$ M decreased the maximal contractile response induced by angiotensin II. Candesartan at a concentration of 1 nM completely inhibited the response to angiotensin II in a concentration range of $10^{-10}$ - $10^{-7}$ M, an angiotensin II concentration which elicited a full concentration-response curve in the absence of candesartan. The dissociation rate of [$^3$H]-candesartan binding from bovine adrenal cortical membranes, *in vitro*, was 5x slower ($t_{½} = 66$ min) than that of [$^{125}$I]-angiotensin II binding ($t_{½} = 12$ min).

**TOXICOLOGY**

**Acute Toxicity**
Table 7  Acute toxicity

<table>
<thead>
<tr>
<th>Route</th>
<th>Species</th>
<th>Sex</th>
<th>LD&lt;sub&gt;50&lt;/sub&gt; Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>intravenous</td>
<td>mouse</td>
<td>female</td>
<td>1,170</td>
</tr>
<tr>
<td></td>
<td></td>
<td>male</td>
<td>1,120</td>
</tr>
<tr>
<td>intravenous</td>
<td>rat</td>
<td>female</td>
<td>1,550</td>
</tr>
<tr>
<td></td>
<td></td>
<td>male</td>
<td>1,350</td>
</tr>
<tr>
<td>oral study with active metabolite</td>
<td>mouse</td>
<td>female</td>
<td>&gt;2,000 mg/kg for all substances</td>
</tr>
<tr>
<td>(candesartan) and related substances</td>
<td></td>
<td>male</td>
<td>tested</td>
</tr>
<tr>
<td>oral</td>
<td>mouse</td>
<td>female</td>
<td>&gt;2,000 mg/kg</td>
</tr>
<tr>
<td>oral</td>
<td>rat</td>
<td>female</td>
<td>&gt;2,000 mg/kg</td>
</tr>
<tr>
<td>oral</td>
<td>dog</td>
<td>male</td>
<td>&gt;2,000 mg/kg</td>
</tr>
<tr>
<td>oral (4 week study)</td>
<td>monkey</td>
<td>female</td>
<td>&gt;60 mg/kg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>male</td>
<td></td>
</tr>
</tbody>
</table>

**Chronic Toxicity**

The toxic potential of candesartan cilexetil was evaluated in a series of repeated-dose oral toxicity studies of ≤26 weeks in rats and ≤1 year in dogs. The "no toxic effect" dosage levels were concluded to be 10 mg/kg/day in the rat and 20 mg/kg/day in the dog.

Table 8  Toxicity upon repeated oral administration

<table>
<thead>
<tr>
<th>Species/Strain</th>
<th>Number of Animals per Group</th>
<th>Duration and Route of Administration</th>
<th>Daily Dose (mg/kg)</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>rat/F344</td>
<td>4 M+4 F</td>
<td>4 weeks dietary</td>
<td>0 600 2,000 6,000</td>
<td>Food consumption decr. in F at 2,000 mg and in M+F at 6,000mg dose level. Urea N&lt;sub&gt;2&lt;/sub&gt; incr. in M at ≥ 600 mg dosing, and in F at 6,000 mg dosing. Erythrocyte count, hematocrit value, hemoglobin concentration decr. in ≥ 2,000 mg groups. Extramedullary hemapoiesis in all male spleens, hypopcellularity in bone marrow of 2 F and gastric ulcer/erosion in 2 F of 6,000mg group. Hypertrophy of juxtaglomerular cells in kidneys and atrophy of zona glomerulosa in adrenal gland in all treated groups -- expected pharmacological responses. “No toxic effect”: 2,000 mg/kg/day.</td>
</tr>
<tr>
<td>Species/Strain</td>
<td>Number of Animals per Group</td>
<td>Duration and Route of Administration</td>
<td>Daily Dose (mg/kg)</td>
<td>Results</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------------------</td>
<td>-------------------------------------</td>
<td>-------------------</td>
<td>---------</td>
</tr>
<tr>
<td>rat/F344</td>
<td>10 M+10 F</td>
<td>13 weeks dietary</td>
<td>0 300 1,000 3,000</td>
<td>No deaths. Body weight gain suppression in M at ≥ 1,000 mg level. Slight decr. in erythrocyte count, hematocrit value, hemoglobin concentration in F of 300 mg group, M+F at ≥ 1,000 mg dose. Incr. inorganic phosphorus in all M groups, decr. Triglycerides (≥ 1,000 mg male group) and incr. cholesterol (3000 mg male group).</td>
</tr>
<tr>
<td>rat/F344/ Jcl</td>
<td>10 M+10 F</td>
<td>26 weeks oral</td>
<td>0 1 10 100 1,000</td>
<td>No treatment-related deaths, nor abnormal appearance, clinical signs, opthalmoscopy and urinalysis. Decr. in body weight gain and food consumption (M, 1000 mg dose, week 25). H2O intake + urine output incr. (M, 100, 1,000 mg dose). RBC parameter values decr. (M: 10-1,000 dose; F: 100-1,000 dose). Heart wt. decr. in all except M at 1 mg dose. Ratio of kidney wt/body wt. incr. in M ≥ 10 mg dose, and in F ≥ 100 mg dose level. In M at 1000 mg level, incr. in adrenal wt., decr. in thymus wt. Hypertrophy of juxtaglomerular cell and intimal proliferation of interlobular arteries on kidneys of M+F at 10-1,000 mg. Minor incr. in erosion of stomach in M+F at 1,000 mg. “No toxic effect”: 10 mg/kg/day.</td>
</tr>
<tr>
<td>rat/F344/Jcl</td>
<td>10 M+10 F</td>
<td>2 week study of candesartan cilexetil and rel.substances, oral</td>
<td>300 (283.2 mg can.cil. + 16.8mg rel. sub.)</td>
<td>No effects by related substances on the changes caused by candesartan cilexetil alone. No toxic effects caused by related substances.</td>
</tr>
<tr>
<td>dog/Beagle</td>
<td>3 M+3 F</td>
<td>29-31 days oral gavage</td>
<td>0 20 100 300</td>
<td>No animals died during dosing. Decr. erythrocyte parameters in 1 F in each of 100 mg and 300 mg groups. Dark red focus in stomach mucosa in 1 F at 300 mg dose level. Regeneration of tubular epithelium and dilatation of kidney tubules in 1 F at 100 mg level, 2 F at 300 mg level. Mononuclear cell infiltration in kidney in 2 F in both 100 mg and 300 mg groups. Erosion of stomach mucosa in 1 F at 300 mg. No testicular abnormalities. “No toxic effect”: 20 mg/kg/day.</td>
</tr>
<tr>
<td>dog/Beagle</td>
<td>4 M+4 F</td>
<td>26 weeks oral</td>
<td>0 4 20</td>
<td>Suppression of body wt. and decr. erythrocyte parameters in F at 100 mg. Hypertrophy of juxtaglomerular cells at all</td>
</tr>
</tbody>
</table>
Table 8  Toxicity upon repeated oral administration

<table>
<thead>
<tr>
<th>Species/Strain</th>
<th>Number of Animals per Group</th>
<th>Duration and Route of Administration</th>
<th>Daily Dose (mg/kg)</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>100</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>dosage levels. Plasma levels of candesartan cilexetil dose-dependent.</td>
<td></td>
</tr>
<tr>
<td>dog/Beagle</td>
<td>4 M+4 F</td>
<td>52 weeks oral</td>
<td>0, 4, 20, 100, 300</td>
<td>No clinical signs, effects on body wt., food consumption, physiological measurements, urine output, H\textsubscript{2}O intake, hematology, coagulation, or organ wts. Hypertrophy of juxtaglomerular cells at all dosage levels. Regeneration of renal tubule incr. in 100-300 mg dose groups. Plasma levels of candesartan cilexetil and metabolite M II dose-dependent. “No toxic effect” at 20 mg/kg/day in dog.</td>
</tr>
</tbody>
</table>

Reproductive and Developmental Studies

Fertility
In studies concerning male and female rat fertility, no adverse effects were found on the reproductive organs. Mating performance, fertility and necropsy findings were unaffected by candesartan cilexetil treatment of males at 0-300 mg/kg/day from 9 weeks before mating to the day before necropsy, and similar findings were observed in females treated from 2 weeks before mating to day 7 of gestation. Fetuses showed no treatment-related abnormalities in mortality, weight, sex ratio, placentae or upon external, visceral or skeletal examinations.

Effects on the development of the kidneys
Animal studies with candesartan cilexetil have demonstrated late fetal and neonatal injury in the kidney. The mechanism is believed to be pharmacologically mediated through effects on the renin-angiotensin-aldosterone system (RAAS). The RAAS plays a critical role in kidney development. RAAS blockade has been shown to lead to abnormal kidney development in very young mice. Administering drugs that act directly on the RAAS, such as ATACAND, can alter normal renal development. Therefore, ATACAND is contraindicated in children <1 year old (see CONTRAINDICATIONS).

Mutagenicity
In vitro studies [bacterial mutagenicity, gene mutation in mammalian (mouse) cells and cytogenic tests (hamster lung cells)] showed that candesartan cilexetil has no mutagenic activity in these systems. Study at the highest doses of the candesartan metabolites (2.5 and 5 mM in the 24-hour treatment series, and 1.25 and 2.5 mM in the 48-hour treatment series) suggested cytotoxicity-mediated clastogenicity as a mechanism for the breakage-type chromosome aberration effects observed. In vivo studies (micronucleus test in mouse and unscheduled DNA synthesis assay in rat) indicate that candesartan cilexetil and its metabolites are neither mutagenic nor clastogenic.
Carcinogenicity

The carcinogenic potential of candesartan cilexetil was studied in rats after administration in the diet for 24 months. Dose levels were 100, 300 and 1000 mg/kg/day (50 male and 50 female rats per group). No alteration in tumour profile was observed. A 2-year oral gavage study of candesartan cilexetil in mice was performed at daily dosages of 3, 10, 30 and 100 mg/kg/day. There was no alteration in the tumour profile.

REFERENCES

Bell TP, DeQuattro V, Lasseter KC, Ruff D, Hardison JD, Cushing D, Kezer AE, Michelson EL.

Delacrétaz E, Nussberger J, Biollaz J, Waeber B, Brunner HR.

Gradman AH, Lewin A, Bowling BT, Tonkon M, Deedwania PC, Kezer AE, Hardison JD, Cushing DJ, Michelson EL.


Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME.
PART III: CONSUMER INFORMATION

Atacand®
(candesartan cilexetil tablets)

Read this carefully before you start taking ATACAND and each time you get a refill. This leaflet is a summary and will not tell you everything about ATACAND. Talk to your doctor, nurse, or pharmacist about your medical condition and treatment and ask if there is any new information about ATACAND.

ABOUT THIS MEDICATION

What the medication is used for:
ATACAND is used to treat:
- High Blood Pressure in Adults
- High Blood Pressure in Children (6 to 17 years of age)
- Heart Failure in Adults

What it does:
ATACAND is an angiotensin receptor blocker (ARB). You can recognize an ARB because its medicinal ingredient ends in "-SARTAN".

This medicine does not cure your disease. It helps to control it. Therefore, it is important to continue taking ATACAND regularly even if you feel fine. Its main action is to relax the arteries, letting the blood flow more freely, thereby lowering the blood pressure.

When it should not be used:
Do not take ATACAND if you:
- Are allergic to candesartan cilexetil or to any non-medicinal ingredient in the formulation.
- Have experienced an allergic reaction (angioedema) with swelling of the hands, feet, or ankles, face, lips, tongue, throat, or sudden difficulty breathing or swallowing, to any ARB. Be sure to tell your doctor, nurse, or pharmacist that this has happened to you.
- Are already taking a blood pressure-lowering medicine that contains aliskiren (such as Rasilez) and you have diabetes or kidney disease.
- Are pregnant or intend to become pregnant. Taking ATACAND during pregnancy can cause injury and even death to your baby.
- Are breastfeeding. It is possible that ATACAND passes into breast milk.
- Are less than 1 year old
- Have one of the following rare hereditary diseases:
  - Galactose intolerance
  - Lapp lactase deficiency
  - Glucose-galactose malabsorption

Because lactose is a non-medicinal ingredient in ATACAND.

What the medicinal ingredient is:
Candesartan cilexetil.

What the nonmedicinal ingredients are:
Calcium carboxymethylcellulose, hydroxypropyl cellulose, iron oxide (except 4 mg tablets), lactose, magnesium stearate, maize starch and polyethylene glycol.

What dosage forms it comes in:
Tablets: 4 mg, 8 mg, 16 mg and 32 mg.

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions - Pregnancy
ATACAND should not be used during pregnancy. If you discover that you are pregnant while taking ATACAND, stop the medication and contact your doctor, nurse, or pharmacist as soon as possible.

Before you use ATACAND talk to your doctor, nurse or pharmacist if you:
- Have experienced an allergic reaction to any drug used to lower blood pressure, including angiotensin converting enzyme (ACE) inhibitors.
- Have narrowing of an artery or a heart valve.
- Have had a heart attack or stroke.
- Have heart failure.
- Have diabetes, heart, liver or kidney disease.
- Are on dialysis.
- Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.
- Are taking a salt substitute that contains potassium, potassium supplements, or a potassium-sparing diuretic (a specific kind of “water pill” that makes your body keep potassium) or other drugs that may increase potassium levels (e.g., heparin, co-trimoxazole).
- Are on a low-salt diet.
- Are taking a medicine that contains aliskiren, such as Rasilez, used to lower high blood pressure. The combination with ATACAND is not recommended.
- Are taking an angiotensin converting enzyme (ACE) inhibitor. You can recognize ACE inhibitors because their medicinal ingredient ends in “-PRIL”.
- Are taking an ACE-inhibitor together with a medicine which belongs to the class of medicines known as mineralocorticoid receptor antagonists (for example, spironolactone, eplerenone). These medicines are for the treatment of heart failure.
Driving and using machines: Before you perform tasks which may require special attention, wait until you know how you respond to ATACAND. Dizziness, lightheadedness, or fainting can especially occur after the first dose and when the dose is increased.

If you are currently taking ATACAND and are going to have an operation, be sure to tell your doctor or dentist about your medication before you are given an anaesthetic.

INTERACTIONS WITH THIS MEDICATION

As with most medicines, interactions with other drugs are possible. Tell your doctor, nurse, or pharmacist about all the medicines you take, including drugs prescribed by other doctors, vitamins, minerals, natural supplements, or alternative medicines.

The following may interact with ATACAND:
- Agents increasing serum potassium, such as a salt substitute that contains potassium, potassium supplements, potassium-sparing diuretic (a specific kind of “water pill”), or other drugs that may increase potassium levels (e.g., heparin, co-trimoxazole).
- Lithium used to treat bipolar disease.
- Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and swelling. Examples include ibuprofen, naproxen, and celecoxib.
- Blood pressure-lowering drugs, including diuretics (“water pills”), aliskiren-containing products (e.g. Rasilez) or angiotensin converting enzyme (ACE) inhibitors.
- Mineralocorticoid receptor antagonists (for example, spironolactone, eplerenone) and ACE inhibitors used in Heart failure.

PROPER USE OF THIS MEDICATION

The dosage of ATACAND is individualized.

Take ATACAND exactly as prescribed. It is recommended to take your dose at about the same time everyday.

ATACAND is taken once a day. Even if your doctor has prescribed 2 tablets a day, both should be taken at the same time, unless otherwise indicated.

ATACAND may be taken with food or on an empty stomach but it should be taken consistently the same way each day.

Swallow ATACAND with a glass of water.

How to use the blister packs:
- As an aid to help you keep track of your doses, ATACAND comes in a blister pack. The days of the week are printed on the back of the blister. To start, take the tablet that matches the day of the week. Continue taking the tablets in order, until they are all finished.
- There are 14 days of labeled tablets in each blister, with one extra to make 15. All 15 tablets, including the one labeled “Take this tablet last”, are exactly the same. Once you have finished the 14 labeled tablets, take the one marked "Take this tablet last" before starting your next blister pack.

Usual Dose:
Lower doses may be required based on the other medications you take and the presence of other disease conditions.

High Blood Pressure in Adults:
Recommended Initial Dose: 16 mg once a day.
Total Daily Dose: 8 mg to 32 mg once a day.

High Blood Pressure in Children (6 to 17 years of age):
- For children who weigh less than 50 kg:
  Recommended Starting Dose: 4 mg once a day.
  Maximum Dose: 8 mg once a day
- For children who weigh 50 kg or more:
  Recommended Starting Dose: 8 mg once a day.
  Maximum Dose: 16 mg once a day

Heart Failure in Adults:
Usual Recommended Initial Dose: 4 mg once a day.
If tolerated by the patient, this dose is gradually doubled (approximately every 2 weeks) until the target dose is reached.
Target Dose: 32 mg once a day.

Overdose:
In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Missed Dose:
If you miss a dose of ATACAND and remember within 12 hours, you should take your usual dose as soon as possible. Then go back to your regular schedule. But if it is more than 12 hours when you remember, do not take the missed dose. Just take the next dose on time.

Never take a double dose of ATACAND to make up for missed tablets. If you are still unsure, check with your doctor or pharmacist to see what you should do.
### SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Side effects may include:
- Dizziness, falls
- Drowsiness, insomnia
- Rash
- Diarrhea, vomiting
- Headache
- Back or leg pain, muscle cramps
- Cough
- Sore throat
- Dry mouth
- Cold symptoms
- Pneumonia
- Fainting spells
- Confusion

Side effects in adults and children are similar, but may occur more often in children.

If any of these affects you severely, tell your doctor, nurse or pharmacist.

ATACAND can cause abnormal blood test results. Your doctor will decide when to perform blood tests and will interpret the results.

### SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor, nurse or pharmacist</th>
<th>Stop taking drug and seek immediate medical help</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low Blood Pressure: dizziness, fainting, lightheadedness</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Fast, Slow or Irregular Heart Beat</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Increased levels of potassium in the blood: irregular heartbeats, muscle weakness and generally feeling unwell</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allergic Reaction: rash, hives, swelling of the face, lips, tongue or throat, difficulty swallowing or breathing</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Kidney Disorder: change in frequency of urination, nausea, vomiting, swelling of extremities, fatigue</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Hematuria (blood in urine)</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Liver Disorder: yellowing of the skin or eyes, dark urine, abdominal pain, nausea, vomiting, loss of appetite</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Shortness of breath, difficulty breathing (Dyspnea, Pulmonary edema)</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rhabdomyolysis: muscle pain that you cannot explain, muscle tenderness or weakness, dark brown urine</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Very rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased Platelets: bruising, bleeding, fatigue and weakness</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammation of the Pancreas: abdominal pain that lasts and gets worse when you lie down, nausea and vomiting</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Chest Pain</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor, nurse or pharmacist</th>
<th>Stop taking drug and seek immediate medical help</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroke (cerebrovascular accident): face or arm weakness, abnormal speech and blurred vision, loss of consciousness</td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
</tbody>
</table>

This is not a complete list of side effects. For any unexpected effects while taking ATACAND, contact your doctor, nurse or pharmacist.

HOW TO STORE IT

- When you first open the package, if you find any damage to the plastic seal or foil which exposes the tablet, ask your pharmacist to check the package.
- ATACAND tablets are protected in their package, it is best to keep the tablets in their original package at normal room temperature and in a dry place. Do not keep ATACAND in the bathroom.
- Keep out of sight and reach of children. Never take medicine in front of small children as they will want to copy you.
- Do not keep or use ATACAND after the expiry date indicated on the package. Unused medicines which you know you will no longer need should be carefully discarded. You may wish to seek advice from your pharmacist.
- Remember to get a new prescription from your doctor or a refill from your pharmacy a few days before all your tablets are taken.

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at www.healthcanada.gc.ca/medeffect
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to: Canada Vigilance Program
  
Health Canada
Postal Locator 0701E
Ottawa, ON K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

NOTE: This CONSUMER INFORMATION leaflet provides you with the most current information at the time of printing. For the most current information, the Consumer Information Leaflet plus the full Product Monograph, prepared for health professionals can be found at: www.astrazeneca.ca, or by contacting the sponsor, AstraZeneca Canada Inc. at: Customer Inquiries – 1 (800) 668-6000, Renseignements – 1 (800) 461-3787.

This leaflet was prepared by: AstraZeneca Canada Inc. Mississauga, Ontario L4Y 1M4

ATACAND® and the AstraZeneca logo are registered trademarks of the AstraZeneca group of companies. Manufactured under license from Takeda Pharmaceutical Company Ltd.

Last revised: February 19, 2016